Molecular Partners Ag (MOLN) Assets Average (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Assets Average of $56033.7 for Q1 2026, down 100.0% year-over-year from $78.6 billion in Q1 2025, and down 20.14% quarter-over-quarter from $70163.8 in Q4 2025.
Molecular Partners Ag (MOLN) Assets Average (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Assets Average for 6 consecutive years, with $56033.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 100.0% year-over-year to $56033.7; the TTM figure through Mar 2026 stood at $56033.7 (down 100.0% YoY), while the FY2025 annual figure was $90.5 million, down 55.27% from the prior year.
- Assets Average eased to $56033.7 in Q1 2026 per MOLN's latest filing, from $70163.8 in the prior quarter.
- Across five years, Assets Average topped out at $169.0 billion in Q2 2022 and bottomed at $56033.7 in Q1 2026.
- Historically, Assets Average has averaged $99.4 billion across 5 years, with a median of $106.4 billion in 2024.
- Annual changes were most pronounced in 2022 — Assets Average jumped 51.56% — and 2026, when it tumbled 100.0%.
- Molecular Partners Ag's Assets Average stood at $145.7 billion in 2022, then fell by 15.18% to $123.6 billion in 2023, then declined by 27.91% to $89.1 billion in 2024, then slumped by 100.0% to $70163.8 in 2025, then slipped by 20.14% to $56033.7 in 2026.
- Business Quant data shows MOLN's Assets Average at $56033.7 in Q1 2026, $70163.8 in Q4 2025, and $70174.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | 56,033.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,033.71 |
| Dec 31, 2025 | 70,163.77 |
| Sep 30, 2025 | 70,174.93 |
| Jun 30, 2025 | 78.47 Bn |
| Mar 31, 2025 | 78.56 Bn |
| Dec 31, 2024 | 89.09 Bn |
| Sep 30, 2024 | 89.09 Bn |
| Jun 30, 2024 | 106.42 Bn |
| Mar 31, 2024 | 106.43 Bn |
| Dec 31, 2023 | 123.58 Bn |
| Sep 30, 2023 | 123.60 Bn |
| Jun 30, 2023 | 132.32 Bn |
| Mar 31, 2023 | 132.33 Bn |
| Dec 31, 2022 | 145.70 Bn |
| Sep 30, 2022 | 145.72 Bn |
| Jun 30, 2022 | 168.99 Bn |
| Mar 31, 2022 | 168.93 Bn |
| Dec 31, 2021 | 96.14 Bn |